Healius share price on watch after trading update

The Healius Ltd (ASX: HLS) share price is on watch as the Aussie healthcare company provided a trading update at its AGM today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is on watch this morning after a trading update provided at the company's annual general meeting (AGM).

What could move the Healius share price?

While shareholders are waiting to hear from management at the AGM, all eyes will be on the company's trading and management update released this morning.

Healius announced underlying net profit after tax (NPAT) for FY20 is expected to be between $94 million and $102 million, which could see the Healius share price move today.

At the top end of that range, this would represent a 9.4% increase on the prior corresponding period (pcp) as anticipated in the company's 16 August update. Healius would then have delivered in line with the seasonally adjusted run rate from 2H 2019.

The Aussie healthcare company also confirmed a raft of management changes in today's announcement. Scott Beattie will be taking over as CEO of the group's Medical Centres business. These changes all form part of Healius' organisational re-design, which was announced earlier this year.

What else did Healius announce?

Chairman Rob Hubbard noted FY19 was a big year for the Aussie healthcare group. The company rebranded as Healius during the year and rejected a takeover bid from its major shareholder, Jangho, due to share price and conditionality.

In terms of financials, Healius delivered revenue up 6% on pcp to $1.8 billion with underlying NPAT up 6.5% to $93 million as the Healius share price climbed higher in 2019.

Pathology was the company's largest division, with about 60% of the group's profit on the back of a 2H 2019 turnaround. Healius' Medical Centres division grew revenue and EBIT by 13% and 19%, respectively, and the Imaging division delivered a third successive year of double-digit growth.

Mr. Hubbard said FY20 will be the peak year of adjustments to the company's reported earnings. 

Capital expenditure remained higher in FY19, mostly due to strategic investments such as its Montserrat Day Hospitals acquisition.

The Healius share price is up 27.87% to $3.12 per share, prior to this morning's open.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »